Sopharma AD reports sale of treasury shares totaling BGN 166,787

Ognian Ivanov Donev
Ognian Ivanov Donev
0Comments

Sopharma AD has announced the sale of 68,049 treasury shares on August 20, 2025. The transaction took place on the Bulgarian Stock Exchange at a total value of BGN 166,787.20, with an average price per share of BGN 2.45.

The company stated that these shares represent 0.01% of its share capital. Following this sale, Sopharma AD holds a total of 20,965,783 treasury shares, which accounts for 3.89% of its share capital.

According to the company, “Sopharma” AD (SFA: Bulgarian Stock Exchange, SPH: Warsaw Stock Exchange) notifies that on August 20, 2025 the Company sold 68 049 (sixty-eight thousand and forty-nine) treasury shares representing 0.01% of the share capital of the Company, at a total value of BGN 166 787.20 on the Bulgarian Stock Exchange, the average price per share was BGN 2.45.”

No further details about future plans for additional transactions were provided in this notification.



1 Comments
  • accounts.binance.info prihlásení says:
    Your comment is awaiting moderation. This is a preview; your comment will be visible after it has been approved.
    Can you be more specific about the content of your article? After reading it, I still have some doubts. Hope you can help me. https://accounts.binance.info/register-person?ref=IHJUI7TF
  • Related

    Paul Hudson Chief Executive Officer Sanofi SA

    Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

    Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

    Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

    Volvo announces updated share and vote count after series conversion

    The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

    Paul Hudson Chief Executive Officer Sanofi SA

    Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

    Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

    Trending

    The Weekly Newsletter

    Sign-up for the Weekly Newsletter from EU Business Daily.